RPS28

Across TCGA pan-cancer cohorts, RPS28 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPS28 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPS28 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPS28 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where RPS28 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.590	0.888	.011	12	view →
CCRCC	OS	Tertile	All	0.888	1.000	.014	7	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
LUAD	OS	Median	III,IV	1.000	0.704	.018	5	view →
HNSC	DFS	Tertile	All	0.576	0.978	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPS28–PDAC (OS)

Open the PDAC breakdown →